Development of Optimized Bispecific Therapeutics

G. Jonah Rainey, *MedImmune, A member of the AstraZeneca Group* and Changshou Gao, *MedImmune, A member of the AstraZeneca Group*

Many factors contribute to the success or failure of bispecific therapeutics from research through development stages. We employ a toolbox approach to allow optimization of spacing geometry, valency, affinity, and stabilization strategies to generate optimally effective and developable drug candidates. Comparisons across different bispecific platforms as well as case studies of successful drug candidate development will be presented.